Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases1
| Autor: | David P. Figgitt, Greg L. Plosker, Therese M Chapman |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Bifidobacterium longum Gastroenterology Microbiology law.invention chemistry.chemical_compound Probiotic Maintenance therapy Mesalazine law Internal medicine Multicenter trial Medicine Pharmacology (medical) Pharmacology biology business.industry food and beverages General Medicine Pouchitis Balsalazide medicine.disease biology.organism_classification Ulcerative colitis chemistry business Biotechnology |
| Zdroj: | BioDrugs. 21:61-63 |
| ISSN: | 1173-8804 |
| DOI: | 10.2165/00063030-200721010-00007 |
| Popis: | VSL#3 (VSL#3) is a high-concentration probiotic preparation of eight live freeze-dried bacterial species that are normal components of the human gastrointestinal microflora, including four strains of lactobacilli (Lactobacillus casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), three strains of bifidobacteria (Bifidobacterium longum, B. breve, and B. infantis), and Streptococcus salivarius subsp. thermophilus. Data from noncomparative trials suggest that VSL#3 has clinical potential in the treatment of active mild to moderate ulcerative colitis and as maintenance therapy for patients with ulcerative colitis in remission. In addition, a randomized, open-label, multicenter trial showed that VSL#3 in combination with low-dose balsalazide (a prodrug of mesalazine [mesalamine; 5-aminosalicylic acid]) was more effective than standard doses of basalazide or mesalazine monotherapy in the treatment of acute mild to moderate ulcerative colitis. Randomized, double-blind, placebo-controlled studies have shown VSL#3 is effective in preventing the onset of acute pouchitis in patients with newly formed surgical pouches, and in maintaining remission following antibacterial treatment of acute pouchitis in patients with a history of refractory or recurrent pouchitis. Treatment guidelines from the US and the UK include VSL#3 as a therapeutic option for the prevention of pouchitis relapse in patients with chronic pouchitis. In general, VSL#3 was well tolerated in clinical trials. Large, well designed, controlled confirmatory clinical trials will further determine the place of VSL#3 in the treatment of ulcerative colitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|